<DOC>
	<DOC>NCT00398216</DOC>
	<brief_summary>This study is to assess if DU176b is effective in prevention of blood clots following hip replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up visits.</brief_summary>
	<brief_title>A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<criteria>1. 18 years of age or older; male or female. 2. Able to provide written informed consent. 3. Must be scheduled for elective unilateral total hip replacement surgery. Only primary surgeries accepted. 4. If female, must be either one year postmenopausal, surgically sterile, or using medically accepted contraceptive measures as judged by the Investigator and in accordance with local regulatory requirements.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Anti-coagulant</keyword>
	<keyword>hip replacement</keyword>
	<keyword>hip replacement surgery</keyword>
	<keyword>unilateral hip replacement surgery</keyword>
	<keyword>DeepVein Thrombosis</keyword>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>pulmonary embolism</keyword>
	<keyword>Prevention of Blood Clots</keyword>
</DOC>